Yes its true its not certain until they have a successful phase 3, FDA approved clinical trial. But the level of success achieved by the phase 2 trial was very good, the trial size was large, and previously that was good enough to get a significant deal from a major pharmaceutical company. If a deal to fund the phase 3 trial and take the drug to market is struck, it won't be based on "nothing".
They have another large trial result reporting in maybe Jan or Feb 2020 for a second application (Diabetic Macular Oedema). If that is also successful then 1. It significantly increases the size and value of the potential market, and 2. It should increase the level of confidence that OPT302 treatment has good efficacy (it works better in combination with the existing treatment). So that should add a lot of value to the treatment and confidence in the company.
- Forums
- ASX - By Stock
- OPT
- price target
price target, page-59
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
90.5¢ |
Change
-0.010(1.09%) |
Mkt cap ! $1.114B |
Open | High | Low | Value | Volume |
91.5¢ | 91.8¢ | 89.5¢ | $1.036M | 1.140M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 31954 | 89.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
91.5¢ | 71302 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 31954 | 0.895 |
4 | 8312 | 0.890 |
3 | 61000 | 0.880 |
6 | 49472 | 0.870 |
3 | 27500 | 0.865 |
Price($) | Vol. | No. |
---|---|---|
0.915 | 71302 | 3 |
0.920 | 108396 | 8 |
0.925 | 28995 | 3 |
0.930 | 1075 | 1 |
0.940 | 42001 | 3 |
Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
Featured News
SBW
Shekel Brainweigh reports a 50% revenue increase in its Retail Innovation suite and delivers the first batch of 20 Smart Bays to Hitachi as part of a larger order
BM8
Learn of the ASX-listed company that is well-placed to respond to the future global energy demand
OPT (ASX) Chart |
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online